To this end, we generated five different BCR-ABL1 transcripts: three previously identified in CML patients (BCR-ABL1INS/Del, BCR-ABL1e13a3 and BCR-ABL1e14a3), and two (BCR-ABL1∆DC2 and BCR-ABL1∆SH3) artificially engineered to investigate the role of the DC2 (in BCR) and SH3 (in ABL1) domains. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.